Clinical Trials

MSHO Supports Cancer Clinical Research Efforts in Michigan

MSHO is committed to furthering the advancement of cancer care by supporting the many organizations that provide cancer clinical trials to Michigan's cancer patients.

With clinical trials being performed in Michigan at our four prestigious academic medical centers and six successful NCI Community Clinical Oncology Programs (CCOPs), cancer patients of Michigan should be able to consider a cancer clinical trial as a potential treatment option for their disease.

The Society has a long history of involvement in efforts to further Cancer Clinical Trial participation. MSHO was a  co-convener of Michigan Cancer Consortium Clinical Trials Action Plan to double enrollment in Michigan Cancer Clinical Trials .


Our most significant contribution to advance clinical trial recruitment and retention was acting as facilitator of Michigan Working Group to Improve Cancer Outcomes' 'Consensus Guidelines for Healthcare Coverage of Routine Patient Care Costs Associated with Oncology Clinical Trials.'

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer

NCI-2015-00128, NRG-BR1428, NCT02488967

Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery

NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer

S0820, NCI-2012-02067, SWOG-S0820, NCT01349881

Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer

NCI-2012-01995, CDR0000738280, S1207/NSABP B-53, SWOG-S1207, NCT01674140